MDS Acquires Blueshift Biotechnologies | GenomeWeb
NEW YORK (GenomeWeb News) – MDS said today that its MDS Analytical Technologies unit has acquired cell imaging products firm Blueshift Biotechnologies for $13 million.
 
Sunnyvale, Calif.-based Blueshift makes the IsoCyte benchtop instrument, which performs rapid image analysis of large populations of cells in a microtiter plate whole-well format. According to Toronto-based MDS, Blueshift has placed 14 of the IsoCyte instruments with academic, biotech, and pharmaceutical customers.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.